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Sirtuins are highly conserved lysine deacetylases involved in ageing, energy production, and lifespan extension. The mammalian
SIRT2 has been implicated in Parkinson’s disease (PD) where studies suggest SIRT2 promotes neurodegeneration. We therefore
evaluated the effects of SIRT2 manipulation in toxin treated SH-SY5Y cells and determined the expression and activity of SIRT2 in
postmortem brain tissue from patients with PD. SH-SY5Y viability in response to oxidative stress induced by diquat or rotenone
was measured following SIRT2 overexpression or inhibition of deacetylase activity, along with 𝛼-synuclein aggregation. SIRT2 in
human tissues was evaluated using Western blotting, immunohistochemistry, and fluorometric activity assays. In SH-SY5Y cells,
elevated SIRT2 protected cells from rotenone or diquat induced cell death and enzymatic inhibition of SIRT2 enhanced cell death.
SIRT2 protection wasmediated, in part, through elevated SOD2 expression. SIRT2 reduced the formation of 𝛼-synuclein aggregates
but showed minimal colocalisation with 𝛼-synuclein. In postmortem PD brain tissue, SIRT2 activity was elevated compared to
controls but also elevated in other neurodegenerative disorders. Results from both in vitro work and brain tissue suggest that SIRT2
is necessary for protection against oxidative stress and higher SIRT2 activity in PD brain may be a compensatory mechanism to
combat neuronal stress.
1. Introduction
The mammalian Sirtuin, SIRT2, is a nicotinamide adenine
diphosphate (NAD+) dependent cytoplasmic protein and an
orthologue to yeast Hst2p [1]. SIRT2, though predominantly
a cytoplasmic protein, shuttles between the cytoplasm and
nucleus depending upon the cell cycle stage [2]. Human
SIRT2 deacetylates a number of cytoplasmic and nuclear
proteins and thus is a key modulator of many cellular pro-
cesses including cell cycle, cell motility, autophagy, metabolic
homeostasis, myelination, apoptosis, antioxidant defence
mechanisms, and tumorigenesis. Although all SIRTs are
expressed in the brain, SIRT2 is the most abundant [3] and
is expressed in nearly all brain regions with particularly high
levels in myelin- producing oligodendrocytes (OL) [4, 5]. In
the mouse, isoform 2 of SIRT2, SIRT2.2 is highly expressed
in the adult brain and age related accumulation of SIRT2.2
is observed in both the mouse and human cortex [3]. SIRT2
regulates myelin formation by deacetylating alpha-tubulin
(Lysine 40) in OL [4] and deacetylating Par-3 (protease
activated receptor) in Schwann’s cells [6]. While being a
modulator of OL differentiation, SIRT2 is also suggested to
have a role in regulation of neurite growth and neuronal
motility in hippocampal neurones [7].These findings indicate
that SIRT2 influences axonal plasticity andplays an important
role in maintenance of neuronal networks in the brain and
hence may be involved in age related neurodegenerative
disorders such as Parkinson’s disease (PD).
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Parkinson’s disease is the most common neurodegenera-
tive movement disorder [8, 9] and typically involves progres-
sive loss of dopaminergic (DA) neurones in the substantia
nigra (SN) and accumulation of cytoplasmic inclusions, Lewy
bodies (LB) and Lewy neurites composed of alpha-synuclein
(𝛼-synuclein) [10]. PD is clinically characterised by tremor,
rigidity, bradykinesia, postural instability, and other accom-
panying symptoms [11]. Given the role of SIRTs in fundamen-
tal cell processes and protection from age related changes, the
role of SIRT2 has begun to be studied in neurodegeneration.
Inhibition of SIRT2 in cellular and drosophila models of
PD reduces 𝛼-synuclein mediated toxicity [12]. Rotenone
treatment of rats which causes SN cell death appears in part to
rely on SIRT2 with treatment leading to an elevation of SIRT2
in the SN leading to worsening motor impairment while
inhibition of SIRT2 diminished striatal DA depletion and
improved behaviour abnormality [13]. Conversely, reduction
of SIRT2 causes cell death in neural PC12 cells [14] and also in
BV2microglia [15, 16], with increased SIRT2 activity rescuing
microtubule dynamics in SH-SY5Y cells [17]. Ablation of
SIRT2 in the brain however causes minimal effects and
therefore modulation of SIRT2 activity may be important in
the context of cellular and in particular neuronal stress [18].
Given the possible role of SIRT2 in PD, the present study
evaluated the role of SIRT2 in oxidative stress mediated
cell death and characterised its role in PD. The effects of
overexpression of SIRT2 and inhibition of deacetylase activity
of SIRT2 were determined in oxidative stress in SH-SY5Y
cells using diquat or rotenone, which induce cellular and
mitochondrial stress, respectively [19, 20].The effect of SIRT2
on𝛼-synuclein aggregate formation in toxin treated SH-SY5Y
cells was also evaluated. We also determined the expression,
activity, and localisation of SIRT2 in postmortem human
brain tissue obtained from the patients with PD, PD with
dementia (PDD), dementia with Lewy bodies (DLB), and
Alzheimer’s disease (AD).
2. Materials and Method
2.1. SH-SY5Y Cells. SH-SY5Y neuroblastoma cells were
obtained from the European Collection of Cell Cultures
(ECACC, Salisbury, UK) and cultured as described pre-
viously [20]. Cells were grown at 37∘C in a humidified
atmosphere of 95% air/5% CO
2
.
2.2. SIRT2 Overexpression and Toxin Treatment in SH-SY5Y
Cells. Wild type SIRT2 (SIRT2pcDNA3.1; Plasmid number
13813) was obtained from Addgene and pcDNA 3.1 was
purchased fromThermoFisher Scientific. SH-SY5Y cells were
seeded in 12-well plates and the cells were transfected with
SIRT2pcDNA3.1 and the control group was transfected with
empty pcDNA3.1 plasmid using PEI (polyethyleneimine;
Invitrogen). Plasmids were incubated with cells at 37∘C
for 48 hours. To study the effect of SIRT2 inhibition, one
set of cells transfected with SIRT2 and pcDNA3.1 were
treated with either diquat (Sigma-Aldrich, UK) dissolved in
PBS (Phosphate buffered saline; Sigma-Aldrich) or rotenone
(Sigma-Aldrich) dissolved in DMSO (dimethyl sulphoxide,
Sigma-Aldrich) at a final concentration of 0.2% PBS/DMSO
alone and a second set of cells with toxin and AGK2 as
a specific SIRT2 inhibitor (25 𝜇M; Tocris, UK; see Supple-
mentary Figure 4 in Supplementary Material available online
at https://doi.org/10.1155/2017/2643587). AGK2 was added to
cells 2 hours prior to diquat or rotenone treatment and the
cells were incubated overnight for 20 hours. Cell viability
was determined by Alamar Blue reduction assay [20] (refer
to Figures 1, 2, and 4 in supplementary files for efficiency of
SIRT2 transfection and inhibition).
2.3. Western Blotting. Following toxicity determination, cell
lysates were prepared by scraping the viable cells in native
lysis buffer (1% 10x Tris buffered saline (TBS), 0.27MSucrose,
1% Triton X-100, 1x protease inhibitor cocktail). The cell
lysates were sonicated for 20 seconds using a sonic probe
and the total protein was determined using Bradford assay
(modified from [21]). Twenty micrograms of protein in cell
lysates were subjected to electrophoresis and were probed
for selected antibodies as described previously [20] (see
Table 1 in supplementary files for dilution and suppliers of
antibodies).
2.4. Fluorescence Immunocytochemistry. SH-SY5Y cells were
grown in chamber slides (BD Falcon, UK), transfected with
SIRT2 plasmids, and treated with diquat or rotenone with or
without AGK2. The cells were washed with PBS and slides
incubated with 4% formaldehyde (Sigma-Aldrich) in warm
1x PBS for 15 minutes and then washed with PBS and stored
until use in 10% glycerol (Sigma-Aldrich, UK) at 4∘C. Cells
were washed and blocked in 1x PBS/5% normal serum/0.3%
Triton X-100 for an hour then incubated overnight at
4∘C with SIRT2 and phospho-𝛼-synuclein (Wako) for 𝛼-
synuclein aggregates. Cells were washed with PBS and incu-
bated with secondary antibodies for 60 minutes protected
from light. Cells were washed with PBS and counterstained
and mounted with ProLong Gold Antifade Mountant with
DAPI (Thermo Fisher). Images were acquired using a Zeiss
Axioplan 2 microscope (Zeiss, Oberkochen, Germany) with
a 40x objective and images captured at 1024 × 1024 pixel
resolution for analysis. Images were quantified using ImageJ
(NIH, Bethesda, USA).The exposure time of the fluorescence
was standardised to empty vector transfected cells with the
same exposure time applied to all other sections with the
SIRT2 overexpressing cells showing reduced 𝛼-synuclein
staining intensity. All stained sections were quantified using
ImageJ (NIH, Bethesda, USA) analysis of confocal images.
The total immunostaining was analysed by importing the
image to ImageJ and binarisation of the image (converted
to 8-bit grey scale) and the highlighted cell area was quan-
tified by using the “analyse particles” function. 𝛼-Synuclein
aggregate immunoreactivity was also determined by using a
standardised custom histogram based coloured thresholding
technique and then subjected to “analyse particles.” The
parameters recorded were total area and percentage area of
staining. 𝛼-Synuclein aggregate percentage was calculated as
the total area of 𝛼-synuclein divided by the total area of
immunostaining multiplied by 100.
Parkinson’s Disease 3
Table 1: Details of brain samples used for Western blot and immunohistochemistry.
Groups FCX TCX Cb Pu Hp Age at death (years) Tissue pH PMD (hours) Gender
M F
Control (𝑁) 11 12 12 12 8 77.5 ± 6.98 6.17 ± 0.34 19.9 ± 6.42 7 5
PD (𝑁) 12 12 12 12 — 77.44 ± 7.03 5.85 ± 0.06 23.44 ± 9.72 8 4
PDD (𝑁) 8 9 12 8 — 75.93 ± 5.38 6.19 ± 0.32 24.69 ± 11.38 9 3
DLB (𝑁) 12 12 12 12 6 77.00 ± 5.35 6.32 ± 0.29 18.0 ± 8.58 9 3
AD (𝑁) 12 12 12 — 9 80.37 ± 5.25 6.19 ± 0.33 19.84 ± 9.30 5 7
The table summarises the case details of brain samples used in Western blot analysis and immunohistochemistry. FCX: frontal cortex; TCX: temporal cortex;
Cb: cerebellum; Pu: putamen; Hp: hippocampus; PMD: postmortem delay.
2.5. Postmortem Tissue Analysis. Brain samples were ob-
tained from Newcastle Brain Tissue Resource, a Human
Tissue Authority licensed tissue bank. All aspects of the
study were approved by the National Research Ethics Service.
Tissue was obtained at postmortem as soon as possible after
death and samples were snap frozen and stored at −80∘C.
Frozen tissue of the relevant regionwas identified and protein
homogenates fromPD,DLB, PDD, AD, and controls (Table 1)
were prepared by homogenising approximately 250mg of
freshly thawed grey matter in 2.5ml of 0.2M triethylammo-
nium bicarbonate (TEAB) containing 1x protease inhibitor.
After addition of 10 𝜇l of 10% SDS to 500 𝜇l of homogenate,
sampleswere vortexed and then sonicated using a sonic probe
for 15 secs, followed by sonication on ice in a sonic bath for
40mins. The concentration of protein was determined by
Bradford assay.Western blottingwas performed as previously
[20].
2.6. Sirtuin Activity. Brain protein homogenates were thawed
and vortexed and sonicated as previous section. Samples were
spun down at 100 g at 4∘C for 5 minutes and the protein
concentration of supernatant was determined by Bradford
assay. Fluorescent SIRT substrate p53 (379–382), Ac-RHKK
(Ac)-AMC was synthesised by Cambridge Research Biolabs,
UK. Stock peptide was prepared as a 5mM solution in diluted
SIRT Assay buffer (50mM Tris-HCl, pH 8.0, containing
137mM sodium chloride, 2.7mM KCl, and 1mM MgCl
2
)
and was stored at −70∘C until use. Total SIRT activity was
determined by using 30 𝜇g protein in substrate buffer con-
taining 41.6 𝜇M peptide, 1mM NAD+, and 100 nM TSA (as
an HDAC inhibitor) and incubated at room temperature for
2 hours on a shaker. After 2 hours 2.5 𝜇g/ml trypsin in 50mM
NAM was added to stop further deacetylation and to cleave
the deacetylated product. The fluorescence was recorded
for each well after one hour of incubation of the trypsin-
NAM solution in the plate reader on excitation wavelength
of 350–360 nm and emission wavelength of 450–460 nm.
SIRT2 activity was determined as AGK2 (20 𝜇M) inhibitable
activity. Use of recombinant SIRT1, SIRT2, and SIRT3 showed
equivalent activity with the Ac-RHKK (Ac)-AMC substrate
(see supplementary files for sample and buffer preparation,
and protein activity).
2.7. Determination of Cellular Localisation of SIRT2. For-
malin fixed paraffin embedded brain tissue sections were
used to determine distribution of SIRT2 in the CNS in
disease. For immunohistochemistry, 10 𝜇M coronal sections
were sampled from the temporal cortex, hippocampus, and
cerebellum. The sections were heated at 60∘C for 10 minutes
followed by 2× 10-minute washes in xylene (Fisher Scientific)
followed by rehydration in decreasing ethanol solutions (2 ×
100%, 95%, 70%, 50%, and 0% ethanol in ddH
2
O). Antigen
retrieval was performed by boiling the sections in heated
citrate buffer (pH 6) in a microwave at high power heat
for 10mins before allowing them to cool for 20 minutes
and then washing them in running tap water. The sections
were then quenched in 30% H
2
O
2
in tap water for 20
minutes followed by 3 × 3-minute washes in TBS-T. Rabbit
monoclonal antibody to SIRT2 (SantaCruz Biotechnology)
dissolved in TBS-T was applied to the sections for an hour
at room temperature followed by 3 × 3-minute washes in
TBS-T. Sections were visualised using Menarini X-Cell Plus
detection system according to the manufacturer’s instruc-
tions with DAB reagent. Sections were counterstained with
haematoxylin dehydrated through graded alcohols to xylene
before coverslips were mounted with DPX (Fisher Scientific).
Images of the sections were acquired using a Zeiss Axioplan
2 microscope (Zeiss, Oberkochen, Germany) with 10x and
63xmagnifying objective and 3-chipCCD true colour camera
(JVC, Yokohama, Japan) coupled to a PC.
2.8. Statistical Analyses. Statistical analysis was performed
using one-way ANOVAwithin groups and two-way ANOVA
within two groups using SPSS21 (IBM) followed by appropri-
ate post hoc (Bonferroni) nonparametric testing. Error bars
represent standard deviation (±SD). ∗𝑝 < 0.05 was con-
sidered statistically significant. Statistical analysis of Western
blotting data was performed in GraphPad prism using a
two-sample 𝑡-test assuming unequal variances. Statistical
significance was considered as 𝑝 < 0.05. The results are
presented as mean ±SD.
3. Results
3.1. SH-SY5Y Cells
3.1.1. Overexpression of SIRT2 Protects Cells from Toxin Medi-
ated Cell Death. Diquat and rotenone have been reported
to induce oxidative stress and rotenone has been shown to
induce parkinsonian symptoms in a rat model [22]. Diquat is
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Figure 1: The effect of SIRT2 overexpression and inhibition was determined in toxin treated SH-SY5Y cells. SIRT2 was overexpressed in
SH-SY5Y cells and control cells were transfected with empty vector following which one set of cells was treated with toxin alone and another
with SIRT2 inhibitor AGK2 and toxin for 20 hours and viability measured by reduction of Alamar Blue. Toxins used: diquat (20𝜇Mor 10 𝜇M)
or rotenone (20𝜇Mor 0.5 𝜇M) treated cells. Data are presented as fold- untreated (±SD) from three independent assays (𝑛 = 3). ∗∗∗𝑝 < 0.001
when compared to 0.2% vehicle (PBS or DMSO), one-way ANOVA (Bonferroni corrected), ###𝑝 < 0.001 and ##𝑝 < 0.01 when compared
to control cells, ∼∼∼𝑝 < 0.001 when compared to control + AGK2 treatment, and $$𝑝 < 0.01 and $𝑝 < 0.05 when compared to SIRT2 cells,
two-way ANOVA (Bonferroni corrected).
a potent redox cycler [23] that upon entry into cells utilises
molecular oxygen to generate O
2
− which can lead to lipid
peroxidation in cell membranes resulting in cell death [24].
In diquat treated cells, overexpression of SIRT2 significantly
increased viability compared to control cells (𝑝 < 0.001). A
significant elevation in cytotoxicity was observed in control
cells coincubated with diquat and AGK2 compared to diquat
alone (20 𝜇Mdiquat: 𝑝 < 0.001 and 10 𝜇Mdiquat 𝑝 < 0.001).
In cells treated with 0.5 𝜇M rotenone, no significant effect
was seen by overexpression or inhibition of SIRT2 (𝑝 >
0.05) but in cells treated with 20𝜇M rotenone, a reduction in
toxicitywas observed in SIRT2 overexpressing cells compared
to control cells and to control cells treated with AGK2 (𝑝 <
0.001) (Figure 1).
3.1.2. Under Oxidative Stress, SIRT2 Induces the Expression
of SOD2. SIRT2 has been shown to increase antioxidant
defence mechanisms by deacetylating FOXO3a and elevating
FOXO3a DNA binding, resulting in an increased expression
of SOD2 [25]. To test this possibility, the levels of SOD2
were measured in diquat or rotenone treated SH-SY5Y cells.
In 20𝜇M diquat treated cells, SOD2 levels were elevated in
control (∼1.5-fold, 𝑝 < 0.001), SIRT2 (∼2-fold, 𝑝 < 0.001),
and SIRT2 + AGK2 cells (∼1.6-fold; 𝑝 < 0.001) compared
to 0.2% PBS treated control cells (Figure 2). The levels of
SOD2 were reduced by 28% in control + AGK2 cells (𝑝 <
0.001) compared to 0.2% PBS treated control cells. In 10 𝜇M
diquat treated cells, SOD2 levels were elevated in control
(∼1.5-fold, 𝑝 < 0.001), SIRT2 (∼1.7-fold, 𝑝 < 0.001), and
SIRT2 + AGK2 cells (∼1.4-fold; 𝑝 < 0.01) compared to 0.2%
PBS treated control cells (Figure 2). The levels of SOD2 were
reduced by 12% in control + AGK2 cells (𝑝 < 0.05) compared
to 0.2% PBS treated control cells. The expression of SOD2
was tested only in 20𝜇M rotenone treated cells, as 0.5 𝜇M
rotenone cells did not show significant difference in cell
viability between the groups (see Figure 1). In addition, at low
levels of rotenone (0.5𝜇M) oxidative damage may be limited
to only the mitochondria leading to mitochondria-mediated
cell death independent of cytoplasmic SIRT2. Higher levels
of rotenone (20𝜇m) with increased oxidative stress and
mitochondrial inhibition leading to marked depletion of cel-
lular ATP could reduce cytoplasmic SIRT2 phosphorylation
causing increased SIRT2 activation [7] leading to induction of
SOD2 and other mediators.The levels of SOD2 were elevated
in control (∼1.3-fold, 𝑝 < 0.01), SIRT2 (∼1.6-fold, 𝑝 < 0.001),
and SIRT2 + AGK2 cells (∼1.4-fold; 𝑝 < 0.001) compared to
0.2% DMSO treated control cells. The levels of SOD2 were
reduced by 17% in control + AGK2 cells (𝑝 < 0.05) compared
to 0.2% DMSO treated control cells (Figure 2).
3.1.3. SIRT2 Shows Minimal Colocalisation with 𝛼-Synuclein.
Cells respond to stress by synthesising stress proteins and/or
by relocalising the proteins to different cellular compart-
ments. SIRT2 is a cytoplasmic protein which can translocate
to the nucleus depending upon the cell cycle stage and
cellular stress [2, 26]. To study the effect of cellular stress
on localisation of SIRT2, SH-SY5Y cells were treated with
diquat or rotenone to induce the stress and the localisation
of SIRT2 was determined using immunocytochemistry and
microscopy. On treatment with diquat or rotenone, SIRT2
was localised both in the nucleus and in the cytoplasm but
was present prominently in the nucleus (see supplementary
Figure 3).The localisation of SIRT2 in the nucleus under toxin
induced oxidative stress could be attributed to the role played
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Figure 2: Expression of SOD2 was measured in toxin treated SH-SY5Y cells. SIRT2 was overexpressed in SH-SY5Y cells and control cells
were transfected with empty vector following which one set of cells was treated with toxin alone and another with SIRT2 inhibitor AGK2 and
toxin. Cells were harvested and the samples were probed for SOD2 expression. Data presented as fold-untreated (0.2% vehicle) (±SD) from
three independent assays (𝑛 = 3). ∗∗∗𝑝 < 0.001, ∗∗𝑝 < 0.01, and ∗𝑝 < 0.05 when compared to 0.2% vehicle, one-way ANOVA (Bonferroni
corrected), ###𝑝 < 0.001 when compared to control cells, ∼∼∼𝑝 < 0.001 when compared to control + AGK2 treatment, and $$$𝑝 < 0.001 and
$$𝑝 < 0.01 when compared to SIRT2, two-way ANOVA (Bonferroni corrected). M indicates molecular weight marker lane.
by SIRT2 in DNA damage repair and cell cycle regulation
under normal circumstances and as well as under genotoxic
stress [27, 28] (Figures 3 and 4).
3.1.4. Inhibition of SIRT2 Enhanced𝛼-Synuclein Aggregate For-
mation. PD involves the progressive loss of DA neurones in
the SN and the presence of LB rich in𝛼-synuclein [10, 29].The
𝛼-synuclein aggregates in LB are generally formed because
of the association of misfolded 𝛼-synuclein proteins and
the levels of misfolded proteins can increase under several
conditions such as oxidative stress [30], inhibition of protein
degradation [31], or mitochondrial dysfunction [32]. SIRT2
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Figure 3: Localisation of SIRT2 and𝛼-synuclein in diquat treated SH-SY5Y cells. Cellular distribution of SIRT2 and phospho-𝛼-synucleinwas
determined using fluorescent immunocytochemistry. Images show 𝛼-synuclein immunostaining, SIRT2 immunostaining, and all staining
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showed minimal colocalisation with 𝛼-synuclein suggesting
that SIRT2 may not physically interact with 𝛼-synuclein
(Figures 3 and 4). The minimal proportion of colocalisation
may potentially be attributed to the interaction of both SIRT2
and 𝛼-synuclein with 𝛼-tubulin [33, 34]. The effect of SIRT2
on 𝛼-synuclein aggregate formation was determined in toxin
and AGK2 treated SH-SY5Y cells. In diquat treated cells, a
significant increase in aggregate formation was seen in AGK2
treated control cells when compared to 0.2% PBS treated
control cells (𝑝 < 0.001). In SIRT2 + AGK2 cells, aggregate
formation was higher than control (𝑝 < 0.01) and SIRT2
cells (𝑝 < 0.001) but was significantly lower than control +
AGK2 (𝑝 < 0.001) cells when treated with 20𝜇M diquat.
Overexpression of SIRT2 inhibited 𝛼-synuclein aggregate
formation in 20 𝜇M diquat treated cells compared to control
cells (𝑝 < 0.001; <23%). In rotenone treated cells, AGK2
treated control (𝑝 < 0.001) and SIRT2 (𝑝 < 0.001) cells
showed increased aggregate formation in all treatments with
SIRT2 overexpression causing reduced aggregate formation
(𝑝 < 0.001) (Figure 5).
3.1.5. SIRT2 Protein in Neurodegeneration. In the frontal
cortex of PD cases, SIRT2.3 and SIRT2.2 isoforms were
detected but not isoforms 1 and 4. Levels of SIRT2 were
elevated, SIRT2.3 by 25% (𝑝 < 0.05) and SIRT2.2 by 30%
(𝑝 < 0.01). In the temporal cortex, no significant difference
was observed in the expression of either isoforms of SIRT2
between control and PD cases (𝑝 > 0.05). In the putamen,
there was no observable difference in the level of SIRT2.3
whereas a reduction of 23% in the expression of SIRT2.2
was observed in PD but the difference was not statistically
significant (𝑝 > 0.05). Western blot analysis of SIRT2
detected only SIRT2.2 in the cerebellum and an increase of
57% was noticed in PD compared to controls (𝑝 < 0.001)
(Figure 6).
In PDD, the levels of SIRT2 isoforms in the frontal
cortex were not changed when compared to controls. In the
temporal cortex, the levels of SIRT2.3 were reduced by 23%
(𝑝 < 0.01) and a nonsignificant reduction of 16% was seen
in SIRT2.2 levels (𝑝 > 0.05). In the putamen, no significant
change in the levels of isoforms of SIRT2 in PDD compared to
controls was observed (𝑝 > 0.05). Similar to PD, only SIRT2.2
was detected in cerebellar samples of PDD and no significant
difference in the levels of SIRT2 was observed between PDD
and control (𝑝 > 0.05) (Figure 7).
In DLB frontal cortex samples, no significant difference
was found in the levels of SIRT2 isoforms when compared to
controls. In the temporal cortex of DLB patients, the levels
of both the isoforms of SIRT2 were elevated, SIRT2.3 by
24% (𝑝 < 0.05) and SIRT2.2 by 33% (𝑝 < 0.01). The
level of SIRT2.3 was significantly reduced in the putamen
of DLB by 13% (𝑝 < 0.05) but no significant difference
was observed in the level SIRT2.2. The levels of SIRT2.2 in
hippocampal samples of DLB were not significantly changed
and in cerebellar samples of DLB, the levels of SIRT2.2
showed an increase of 25% (𝑝 < 0.01) compared to control
(Figure 8).
In AD frontal cortex samples, no significant difference
was observed in the levels of either isoforms of SIRT2
compared to controls. Similarly, no significant differences
were observed in the levels of SIRT2 isoforms in the temporal
cortex. The levels of SIRT2.2 in hippocampal samples were
marginally reduced by 14% compared to controls but not
significantly (𝑝 > 0.05). An increase of 14% was seen in
the levels of SIRT2.2 in the cerebellum of AD compared to
controls (𝑝 < 0.05) (Figure 9).
3.1.6. SIRT2 Activity in Neurodegeneration. In the frontal
cortex, measurement of total SIRT activity did not show any
significant change between the disease groups and controls
(𝑝 > 0.05); however, compared to AD, the total SIRT activity
was reduced in PD and DLB by about 20% (𝑝 < 0.01)
(though PDD did not show any significant difference). SIRT2
activity was upregulated in PD (33%; 𝑝 < 0.001), PDD
(28%; 𝑝 < 0.05), DLB (29%; 𝑝 < 0.01), and AD (31%;
𝑝 < 0.01) compared to controls (𝐹 = 5.906, 𝑝 < 0.001).
In the temporal cortex, there was no significant difference
in total SIRT activity between the disease groups and control
(𝑝 > 0.05); however, compared to AD there was a significant
reduction of 33% in total SIRT activity in PDD (𝑝 < 0.05),
though other groups did not show any significant change.
SIRT2 activity was upregulated in PD (19%; 𝑝 < 0.01), PDD
(17%; 𝑝 < 0.05), DLB (21%; 𝑝 < 0.001), and AD (18%; 𝑝 <
0.01) compared to controls whereas no significant difference
was seen among the disease groups (𝐹 = 5.593; 𝑝 < 0.001)
(Figure 10).
3.1.7. Cellular Location of SIRT2 inHuman Brain. The cellular
localisation of SIRT2 was determined in the temporal cortex,
hippocampus, and cerebellum in PD, PDD, DLB, AD, and
an age matched control group. SIRT2 staining was weak and
localised predominantly in the cytoplasm and nucleus of
large pyramidal neurones in these groups whereas, in AD,
SIRT2 was predominantly localised in pyramidal neurone
cytoplasm. Staining was also apparent in the neuropil in all
cases tested. In the temporal cortex, no apparent difference
was observed within PD, PDD, DLB, and controls (Figure 11;
Supplementary Figure 6). SIRT2 did not show a staining
pattern that appeared to show cortical LB. These results sug-
gest that there was no significant effect of disease conditions
on the location of SIRT2 within the cell. The location of
SIRT2 in different brain regions is summarised in Table 3 in
supplementary files and the location of SIRT2 in other brain
regions is shown in Figure 6 of supplementary files.
4. Discussion
Oxidative stress is a common general mechanism involved in
cell death associated with neurodegenerative disorders [35]
and has been implicated in the initiation and progression
of PD [36]. Studies have reported that inhibition of SIRT2
reduces 𝛼-synuclein mediated toxicity in PD models and
SIRT2 inhibition also rescued cells from mutant HTT in
HD models [12, 37]. In contrast, the findings from this
study suggest that reduced SIRT2 activity increased cell death
following oxidative stress and increasing SIRT2 protects SH-
SY5Y cells and is in agreement with other studies on SIRT2
[14, 17]. As with other SIRTs, SIRT2 is NAD+ dependent
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Figure 5: 𝛼-Synuclein aggregate formation and quantification in toxin treated SH-SY5Y cells. SIRT2 overexpressing SH-SY5Y cells were
treated with toxin (20 𝜇M or 10 𝜇M diquat or 20𝜇M or 0.5 𝜇M rotenone) and 0.2% PBS or DMSO; cells transfected with empty vector were
used as a control and another set of SIRT2 and control cells was coincubated with AGK2 and toxin. Cells were immunostained with phospho-
𝛼-synuclein. Images were captured through GFP filter under 63x magnification. The captured images represent 𝛼-synuclein staining and the
bar graphs represent the aggregate quantification in diquat or rotenone treated cells. Each bar represents %𝛼-synuclein aggregates (±SD) from
three independent assays (𝑛 = 3). ∗∗∗𝑝 < 0.001, ∗∗𝑝 < 0.01, and ∗𝑝 < 0.05 when compared to 0.2% vehicle, one-way ANOVA (Bonferroni
corrected), ###𝑝 < 0.001, ##𝑝 < 0.01, and #𝑝 < 0.05 when compared to control cells, ∼∼∼𝑝 < 0.001, ∼∼𝑝 < 0.01, and ∼𝑝 < 0.05 when compared
to control + AGK2 treatment, and $$$𝑝 < 0.001 and $𝑝 < 0.05when compared to SIRT2 cells, two-way ANOVA (Bonferroni corrected). Scale
bar: 20 𝜇M.
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Figure 6: Expression of SIRT2 in different brain regions in Parkinson’s disease. The levels of SIRT2 were determined in different regions of
PD patients and were compared to a control-cohort. SIRT2 band intensity was normalised with GAPDH. Data are presented as fold change
(±SD) with respect to control from three independent replicates. ∗∗𝑝 < 0.01, and ∗𝑝 < 0.05 when compared to control; statistical analysis
was done through 𝑡-test performed on GraphPad prism. Images are representative blots of SIRT2 and GAPDH.M indicates molecular weight
markers lane.
and is a potential redox sensor and studies have shown that
SIRT2 enhances cell viability under oxidative stress and inhi-
bition or knock-down of SIRT2 decreases intracellular ATP
levels and enhances cell death. SIRT2 can regulate oxidative
stress by deacetylating FOXO3a and increasing expression
of FOXO3a targets, namely, p27Kip1 and SOD2, and under
severe oxidative stress SIRT2 enhances the expression of
the proapoptotic protein Bim [25]. Consequently, through
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Figure 7: Expression of SIRT2 in different regions in Parkinson’s disease with Dementia. The levels of SIRT2 were determined in different
regions of PDD patients and were compared to a control-cohort. SIRT2 band intensity was normalised with GAPDH. Data are presented as
fold change (±SD) with respect to control from three independent replicates. ∗∗𝑝 < 0.01 when compared to control; statistical analysis was
done through 𝑡-test performed on GraphPad prism. Images are representative blots of SIRT2 and GAPDH. M indicates molecular weight
marker lane.
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Figure 8: Expression of SIRT2 in different brain regions in dementia with Lewy Bodies. The levels of SIRT2 were determined in different
regions of DLB patients and were compared to a control-cohort. SIRT2 band intensity was normalised with GAPDH. Data are presented as
fold change (±SD) with respect to control from three independent replicates. ∗∗𝑝 < 0.01, and ∗𝑝 < 0.05when compared to control; statistical
analysis was done through 𝑡-test performed onGraphPad prism. Images are representative blots of SIRT2 andGAPDH.M indicatesmolecular
weight marker lane.
p27Kip1, SIRT2 promotes cell cycle arrest and reduces the
amount of ROS via SOD2 [25]. In this study, the enhanced
expression of SOD2 potentially via FOXO3a following SIRT2
overexpression may be one route by which SIRT2 confers
cellular protection [25]. In PC12 cells, silencing or inhibition
of SIRT2 by AGK2 led to decreased ATP levels and enhanced
cell death via necrosis [14]. In contrast, Nie et al. showed that
inhibition of SIRT2 rescued differentiated PC12 cells from
H
2
O
2
induced toxicity and silencing of SIRT2 reduced the
levels of ROS following H
2
O
2
treatment [38]. These findings
corroborate with results from this study and suggest that the
associated upregulation of SOD2 and SIRT2 can regulate cell
viability and combat oxidative stress.
Cellular stress subjects proteins to a variety of mod-
ifications which affect the stability, activity, and even the
localisation of proteins [39]. In this study it was observed
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Figure 9: Expression of SIRT2 in different brain regions in Alzheimer’s disease. The levels of SIRT2 were determined in different regions of
AD patients and were compared to a control-cohort. SIRT2 band intensity was normalised with GAPDH. Data are presented as fold change
(±SD) with respect to control from three independent replicates. ∗𝑝 < 0.05 when compared to control; statistical analysis was done through
𝑡-test performed on GraphPad prism. Images are representative blots of SIRT2 and GAPDH. M indicates molecular weight marker’s lane.
that under relatively high levels of oxidative stress (20 𝜇M
rotenone, 10 𝜇M, or 20𝜇M diquat), SIRT2 was localised to
the nucleus and cytoplasm but was prominently present in
the nucleus. The absence of any effect of SIRT2 at low levels
of oxidative stress caused by 0.5 𝜇M rotenone may be insuffi-
cient to cause major depletion of ATP and lead to activation
of SIRT2 by dephosphorylation causing SIRT2 to translocate
to the nucleus [7]. SIRT2 is normally a cytoplasmic protein
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Figure 10: Total SIRT and SIRT2 activities in the frontal and temporal cortex in PD, PDD, DLB, AD, and controls. Total SIRT and SIRT2
activities were measured through a fluorometric enzymatic activity assay in the frontal and temporal cortices of PD, PDD, DLB, and AD
patients and were compared to cohort-control group. ∗∗∗𝑝 < 0.001, ∗∗𝑝 < 0.01, and ∗𝑝 < 0.05 when compared to control, one-way ANOVA
(Bonferroni corrected).
but may shuttle to the nucleus based upon cell cycle stage and
cellular stress [2, 26]. Under oxidative stress, the known target
of SIRT2, FOXO3a, shuttles to the nucleus [40] and induces
the expression of its target SOD2 and may directly activate
SOD2 to counteract the effect of ROS [41]. The results from
this study are consistent with previous studies that report that
SIRT2 localises to the cell nucleus under stress. Our finding
that there is no induction of SOD2 in cells overexpressing
SIRT2 under basal conditions would indicate that, following
transfer of SIRT2 to the nucleus during oxidative stress,
SIRT2 may interact with nuclear transcription factors such
as FOXO3a which may lead to the induced expression of
protective proteins such as SOD2.
Given the role of 𝛼-synuclein aggregation in PD, we
found that SIRT2 inhibition enhanced aggregate formation in
diquat or rotenone treated cells with overexpression of SIRT2
reducing 𝛼-synuclein aggregate formation. This contrasts
with previous studies which reported that SIRT2 inhibition
rescues 𝛼-synuclein mediated toxicity [12]. This may be
attributed to different treatment regimens with A53T mutant
𝛼-synuclein overexpression directly aggregating in cellular
and fly models whereas, in this study, 𝛼-synuclein aggre-
gate formation was induced by oxidative stress. The results
obtained from SH-SY5Y cells overexpressing SIRT2 under
basal conditions, or from cells where SIRT2 is inhibited under
basal conditions, suggest that SIRT2 does not promote de
novo 𝛼-synuclein aggregate formation; rather SIRT2 impairs
the formation of new or larger 𝛼-synuclein aggregates. Viabil-
ity assays also corroborate the finding that SIRT2 inhibition
enhances cellular death and SIRT2 overexpression promotes
cell survival. All these findings suggest that SIRT2 acts as a
prosurvival factor under oxidative stress.
The ageing brain shows gene expression changes specif-
ically in the levels of stress response genes, mitochondrial
genes, and genes involved in synaptic function [42]. SIRT2
plays a crucial role in antioxidant defence mechanisms
[25] and in DNA damage repair [43] and elevated lev-
els of oxidative stress and DNA damage are observed in
neurodegenerative disorders such as PD and AD. In this
study, the levels of SIRT2 protein did not show major
or consistent changes in the disease groups compared to
controls, although a tendency towards elevation in the levels
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Figure 11: Cellular distribution of SIRT2 in the temporal cortex of disease and control groups. The images show the cellular localisation of
SIRT2 in grey matter of superior temporal gyrus of temporal cortex in PD, PDD, DLB, AD, and control cases. SIRT2 was localised in both
in the cytoplasm and the nucleus of the neurones in the groups, being predominantly present in the cytoplasm in AD.The picture in inset is
63x oil immersion image overlaid on 10x image. Scale bars, black scale bar = 50𝜇M and red scale bar = 20𝜇M.
of SIRT2 was observed overall. Maxwell et al. showed that
SIRT2 accumulates in the ageing brain [3] and this may
possibly explain why major changes were not observed in
SIRT2 levels in disease groups,with age related changesmask-
ing disease related changes. While protein levels of SIRT2
were essentially unchanged, enzymatic activity for SIRT2
showed SIRT2 activity was higher in disease groups than
control but no significant difference was observed between
neurodegenerative disorders. The current results in induced
oxidative stress in SH-SY5Y cells show SIRT2 overexpression
promotes cell survival and inhibits 𝛼-synuclein aggregate
formation. It is possible that elevated SIRT2 activity in
neurodegenerative disorders is a compensatory mechanism
to counteract the effects of oxidative stress occurring due
to ageing and disease processes. SIRT1 has been shown to
be neuroprotective in different neurodegenerative disorders
and we found that SIRT1 activity was remarkably reduced in
disease groups (unpublished data) although the total SIRT
activity did not differ among the groups. SIRT1 and SIRT2
have been observed to share some targets including p53,
NF-QB, histones H3, and H4 and following down-regulation
of SIRT1 activity it is safe to assume that SIRT2 activity is
elevated to target specific proteins such as p53 and modulate
apoptosis, neuroinflammation, and genomic stability. Also,
in relation to the in vitro work, it is possible that SIRT2 is
upregulated in order to induce the activity of antioxidant
proteins including SOD2 and catalase. Combining the in
vitro and postmortem human tissue studies it is possible that
SIRT2 is required to combat oxidative stress and higher SIRT2
activity in human brain tissue is a compensatory mechanism.
The cellular localisation of SIRT2 showed no significant dif-
ference within the disease groups and controls. Generally, the
sections showed SIRT2 localisation to the cytoplasm but also
nuclei of neurones, which may relate to the translocation of
SIRT2 to the nucleus under stress, corroborating the cellular
work. Future work with additional SIRT2 antibodies would
be needed to determine the location of SIRT2 along with
dual-immunostaining for known neurodegenerative disease
biomarkers. The role of SIRT2 should be further investigated
under chronic oxidative stress in additional neuronal models
of PD.
5. Conclusion
In this study we have shown that, in SH-SY5Y cells, under
diquat or rotenone induced oxidative stress, SIRT2 overex-
pression protected cells from oxidative damage and reduced
𝛼-synuclein aggregate formation. Also, the inhibition of
SIRT2 byAGK2under oxidative stress, elevated cell death and
promoted 𝛼-synuclein aggregate formation. These findings
suggest that SIRT2 promotes cell survival and may provide
this protection through elevation of SOD2. In postmortem
human brain tissue, SIRT2 protein expression did not differ
between different disease groups (PD, PDD, DLB, and AD)
and controls but the enzymatic activity of SIRT2was higher in
disease groups compared to controls. Based upon the findings
from the in vitro work and postmortem brain tissue studies,
elevated SIRT2 in neurodegenerative disorders could be a
compensatory mechanism to combat oxidative stress.
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